{
    "ticker": "ALGS",
    "name": "Aligos Therapeutics, Inc.",
    "description": "Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for viral infections and liver diseases, including chronic Hepatitis B and NASH (non-alcoholic steatohepatitis). Founded in 2018 and headquartered in South San Francisco, California, Aligos utilizes its proprietary technology platforms to create differentiated and effective treatment options. The company is dedicated to addressing significant unmet medical needs in these therapeutic areas. Aligos is advancing several product candidates through clinical trials, including small molecules and monoclonal antibodies that target viral infections or liver disease pathways. Their lead program, a novel entry inhibitor for Hepatitis B, aims to provide a new treatment paradigm for patients suffering from this chronic infection. Aligos is committed to scientific excellence and collaboration, leveraging partnerships with academic institutions and industry leaders to expedite the development of its therapies. The company's mission is to transform patient care through innovative science and provide hope for individuals affected by serious viral diseases and liver conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2018",
    "website": "https://www.aligos.com",
    "ceo": "David A. B. Hill",
    "social_media": {
        "twitter": "https://twitter.com/AligosTx",
        "linkedin": "https://www.linkedin.com/company/aligos-therapeutics/"
    },
    "investor_relations": "https://investors.aligos.com",
    "key_executives": [
        {
            "name": "David A. B. Hill",
            "position": "CEO"
        },
        {
            "name": "Richard A. T. H. Verity",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "HBV Entry Inhibitor",
                "NASH Candidate"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aligos Therapeutics, Inc. | Innovative Solutions for Viral Infections",
        "meta_description": "Explore Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for viral infections and liver diseases. Learn about their advancements in Hepatitis B and NASH treatments.",
        "keywords": [
            "Aligos Therapeutics",
            "Hepatitis B",
            "NASH",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Aligos Therapeutics focused on?",
            "answer": "Aligos Therapeutics is focused on developing innovative therapies for viral infections and liver diseases, including chronic Hepatitis B and NASH."
        },
        {
            "question": "Who is the CEO of Aligos Therapeutics?",
            "answer": "David A. B. Hill is the CEO of Aligos Therapeutics, Inc."
        },
        {
            "question": "Where is Aligos headquartered?",
            "answer": "Aligos is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Aligos's main product candidates?",
            "answer": "Aligos's main product candidates include a novel HBV entry inhibitor and other therapies targeting NASH."
        },
        {
            "question": "When was Aligos Therapeutics founded?",
            "answer": "Aligos Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "GILD",
        "VRNA",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "REGN",
        "VRTX"
    ]
}